- Prescribing Advice for GPs - https://www.prescriber.org.uk -

Once weekly exenatide?

The Lancet has published the results of an open label, randomised, non-inferiority study that compared a weekly formulation of exenatide with the current twice-daily formulation. This trial has been reported in the general media (BBC).

The study ran for 30 weeks and recruited 295 patients with type 2 diabetes. The primary endpoint was change in HbA1c with additional data being collected for body weight and adverse events including hypoglycaemia.

Patients who were treated with the weekly formulation had significantly greater reductions in HbA1c (-1.9% versus -1.5%, p=0.0023). Additionally, a larger proportion of patients reached HbA1c targets of 7% or less (77% versus 61%, p=0.0039). There was no difference in the risk of hypoglycaemia and similar reductions in bodyweight in the two groups.

Action: Clinicians should be aware of this study; media reporting may generate queries. This product is still under development and is therefore not currently available on NHS prescription.